| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | - |
| Drug | Boceprevir |
| Brand | Victrelis® |
| Indication | As add-on therapy to pegylated interferon and ribavirin for the treatment of patients infected with Hepatitis C Genotype 1. |
| Assessment Process | |
| Full submission received from Applicant | 19/08/2011 |
| NCPE assessment completed | 17/01/2012 |
| NCPE assessment outcome | Reimbursement Recommended |
We consider boceprevir a highly cost-effective therapy when added to peginterferon-ribavirin for the treatment of patients infected with genotype 1 hepatitis C virus in the Irish healthcare setting.